Skip to main content
search

Atopic Dermatitis

Hightower’s research has transformed atopic dermatitis management, providing relief and better quality of life.

                       

Know About Atopic Dermatitis Research Study

Atopic dermatitis, known as eczema, is a chronic inflammatory skin condition affecting millions worldwide. It causes dry, itchy, and inflamed patches of skin, disrupting sleep, impacting daily activities, and causing significant discomfort. While current treatments offer some relief, they can be ineffective for many.

We actively managed clinical trials for atopic dermatitis. One involved treating patients with moderate to severe atopic dermatitis for whom standard, approved medicated topical and systemic treatment options were inadequate. The second evaluated the efficacy and safety of a subcutaneous investigational drug.

Current Status

Not Recruiting

Study Count

1

Frequently Asked Questions

How do clinical trial for atopic dermatitis contribute to understanding the disease?

Atopic dermatitis clinical trials play a crucial role in advancing our understanding of the underlying mechanisms, triggers, and treatment options for this chronic inflammatory skin condition.

What types of outcomes are measured in atopic dermatitis clinical trials?

Clinical trials of atopic dermatitis often assess various outcomes to evaluate treatment effectiveness and safety.

How are participants in atopic dermatitis clinical trials monitored for safety?

Specialized physicians monitor participants. Moreover, study protocols typically include regular assessments of vital signs, laboratory tests (such as blood tests), skin examinations, and documentation of any adverse events or side effects experienced by participants.

What happens after an atopic dermatitis clinical trial is completed?

After completing a clinical trial, researchers analyze the data collected to evaluate treatment outcomes, safety, and efficacy. The trial results may be published in scientific journals, presented at medical conferences, or submitted to regulatory authorities for review.

Close Menu